Diagnosis and management of heparin-induced thrombocytopenia

Hematology/Oncology Clinics of North America

Volumn 27, Issue 3, 2013, Pages 541-563

  Lee, Grace M ^a   Arepally, Gowthami M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Heparin; HIT; PF4; PF4 H complexes; Platelet factor 4

Indexed keywords

ARGATROBAN; FONDAPARINUX; HIRULOG; IMMUNOGLOBULIN G; WARFARIN;

BLEEDING; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG HALF LIFE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; LOW DRUG DOSE; LUNG EMBOLISM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTE TRANSFUSION; TREATMENT DURATION;

ALGORITHMS; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 84878241134     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.02.001     Document Type: Review

References (127)

1. Kahn S.R., Lim W., Dunn A.S., et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e195S-e226S.
2. Cuker A., Cines D.B. How I treat heparin-induced thrombocytopenia. Blood 2012, 119:2209-2218.
3. Weismann R.E., Tobin R.W. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg 1958, 76:219-225. [discussion: 25-7].
4. Rhodes G.R., Dixon R.H., Silver D. Heparin induced thrombocytopenia: eight cases with thrombotic-hemorrhagic complications. Ann Surg 1977, 186:752-758.
5. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992, 68:95-96.
6. Suvarna S., Espinasse B., Qi R., et al. Determinants of PF4/heparin immunogenicity. Blood 2007, 110:4253-4260.
7. Kelton J.G., Sheridan D., Santos A., et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988, 72:925-930.
8. Rauova L., Hirsch J.D., Greene T.K., et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 2010, 116:5021-5031.
9. Kasthuri R.S., Glover S.L., Jonas W., et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcgammaRI. Blood 2012, 119:5285-5293.
10. Xiao Z., Visentin G.P., Dayananda K.M., et al. Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood 2008, 112:1091-1100.
11. Greinacher A., Eichler P., Lubenow N., et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000, 96:846-851.
12. Prandoni P., Siragusa S., Girolami B., et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005, 106:3049-3054.
13. Stein P.D., Hull R.D., Matta F., et al. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 2009, 122:919-930.
14. Francis J.L., Palmer G.J., Moroose R., et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 2003, 75:17-22.
15. Ban-Hoefen M., Francis C. Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. Thromb Res 2009, 124:189-192.
16. Martel N., Lee J., Wells P.S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005, 106:2710-2715.
17. Zhou A., Winkler A., Emamifar A., et al. Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for the prevention of deep venous thrombosis?. Chest 2012, 142(5):1175-1178.
18. Rothberg M.B., Pekow P.S., Lahti M., et al. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients. J Hosp Med 2012, 7:457-463.
19. Warkentin T.E., Cook R.J., Marder V.J., et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005, 106:3791-3796.
20. Warkentin T.E., Maurer B.T., Aster R.H. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007, 356:2653-2655. [discussion: 2653-5].
21. Arepally G.M., Ortel T.L. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006, 355:809-817.
22. Warkentin T.E., Sheppard J.A., Sigouin C.S., et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006, 108:2937-2941.
23. Gruel Y., Pouplard C., Lasne D., et al. The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 2004, 104:2791-2793.
24. Rollin J., Pouplard C., Gratacap M.P., et al. Polymorphisms of protein tyrosine phosphatase CD148 influence FcgammaRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. Blood 2012, 120:1309-1316.
25. Pouplard C., Cornillet-Lefebvre P., Attaoua R., et al. Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia. Thromb Res 2012, 129:465-469.
26. Warkentin T.E., Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001, 344:1286-1292.
27. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003, 121:535-555.
28. Greinacher A., Farner B., Kroll H., et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005, 94:132-135.
29. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia 2004, Marcel Dekker Inc., New York. 3rd edition.
30. Schindewolf M., Lindhoff-Last E., Ludwig R.J., et al. Heparin-induced skin lesions. Lancet 2012, 380(9856):1867-1879.
31. Warkentin T.E., Roberts R.S., Hirsh J., et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003, 163:2518-2524.
32. Lewis B.E., Wallis D.E., Leya F., et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163:1849-1856.
33. Warkentin T.E., Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996, 101:502-507.
34. Tardy B., Tardy-Poncet B., Fournel P., et al. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999, 82:1199-1200.
35. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
36. Warkentin T.E., Sheppard J.A., Moore J.C., et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009, 113:4963-4969.
37. Nand S., Wong W., Yuen B., et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997, 56:12-16.
38. Hong A.P., Cook D.J., Sigouin C.S., et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003, 101:3049-3051.
39. Boshkov L.K., Warkentin T.E., Hayward C.P., et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993, 84:322-328.
40. Ernest D., Fisher M.M. Heparin-induced thrombocytopaenia complicated by bilateral adrenal haemorrhage. Intensive Care Med 1991, 17:238-240.
41. Pohl C., Harbrecht U., Greinacher A., et al. Neurologic complications in immune-mediated heparin-induced thrombocytopenia. Neurology 2000, 54:1240-1245.
42. Warkentin T.E., Roberts R.S., Hirsh J., et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005, 127:1857-1861.
43. Carlsson L.E., Lubenow N., Blumentritt C., et al. Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 2003, 13:253-258.
44. Warkentin T.E., Sheppard J.A., Moore J.C., et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005, 146:341-346.
45. Alberio L., Kimmerle S., Baumann A., et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 2003, 114:528-536.
46. Pouplard C., Gueret P., Fouassier M., et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007, 5:1373-1379.
47. Zwicker J.I., Uhl L., Huang W.Y., et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004, 2:2133-2137.
48. Warkentin T.E., Sheppard J.I., Moore J.C., et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008, 6:1304-1312.
49. Mattioli A.V., Bonetti L., Zennaro M., et al. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. Am Heart J 2009, 157:589-595.
50. Bauer T.L., Arepally G., Konkle B.A., et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997, 95:1242-1246.
51. Wallis D.E., Workman D.L., Lewis B.E., et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999, 106:629-635.
52. Reilly M.P., Taylor S.M., Hartman N.K., et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood 2001, 98:2442-2447.
53. Warkentin T.E., Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001, 135:502-506.
54. Rice L., Attisha W.K., Drexler A., et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002, 136:210-215.
55. Everett B.M., Yeh R., Foo S.Y., et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 2007, 83:592-597.
56. Baroletti S., Hurwitz S., Conti N.A., et al. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med 2012, 125:44-49.
57. Yusuf A.M., Warkentin T.E., Arsenault K.A., et al. Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. A systematic review. Thromb Haemost 2012, 107:8-14.
58. Potzsch B., Klovekorn W.P., Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000, 343:515.
59. Linkins L.A., Dans A.L., Moores L.K., et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e495S-e530S.
60. Cuker A. Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost 2011, 106:993-994.
61. Lo G.K., Sigouin C.S., Warkentin T.E. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 2007, 82:1037-1043.
62. Stephan F., Hollande J., Richard O., et al. Thrombocytopenia in a surgical ICU. Chest 1999, 115:1363-1370.
63. Oliveira G.B., Crespo E.M., Becker R.C., et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008, 168:94-102.
64. Baughman R.P., Lower E.E., Flessa H.C., et al. Thrombocytopenia in the intensive care unit. Chest 1993, 104:1243-1247.
65. Pouplard C., May M.A., Iochmann S., et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999, 99:2530-2536.
66. Trossaert M., Gaillard A., Commin P.L., et al. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998, 101:653-655.
67. Selleng S., Selleng K., Wollert H.G., et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost 2008, 6:428-435.
68. Bream-Rouwenhorst H.R., Hobbs R.A. Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia. Pharmacotherapy 2008, 28:1401-1407.
69. Lo G.K., Juhl D., Warkentin T.E., et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006, 4:759-765.
70. Crowther M.A., Cook D.J., Albert M., et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 2010, 25:287-293.
71. Denys B., Stove V., Philippe J., et al. A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res 2008, 123:137-145.
72. Bakchoul T., Giptner A., Najaoui A., et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009, 7:1260-1265.
73. Nellen V., Sulzer I., Barizzi G., et al. Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica 2012, 97:89-97.
74. Bryant A., Low J., Austin S., et al. Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. Br J Haematol 2008, 143:721-726.
75. Cuker A., Arepally G., Crowther M.A., et al. The HIT Expert Probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010, 8:2642-2650.
76. Trehel-Tursis V., Louvain-Quintard V., Zarrouki Y., et al. Clinical and biological features of patients suspected or confirmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU. Chest 2012, 142(4):837-844.
77. Kuitunen A., Suojaranta-Ylinen R., Kukkonen S., et al. A comparison of the haemodynamic effects of 4% succinylated gelatin, 6% hydroxyethyl starch (200/0.5) and 4% human albumin after cardiac surgery. Scand J Surg 2007, 96:72-78.
78. Piednoir P., Allou N., Provenchere S., et al. Heparin-induced thrombocytopenia after cardiac surgery: an observational study of 1,722 patients. J Cardiothorac Vasc Anesth 2012, 26:585-590.
79. Lillo-Le Louet A., Boutouyrie P., Alhenc-Gelas M., et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004, 2:1882-1888.
80. Greinacher A., Juhl D., Strobel U., et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007, 5:1666-1673.
81. McFarland J., Lochowicz A., Aster R., et al. Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia. Am J Hematol 2012, 87:776-781.
82. Amiral J., Peynaud-Debayle E., Wolf M., et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996, 52:90-95.
83. Warkentin T.E., Sheppard J.A., Horsewood P., et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000, 96:1703-1708.
84. Arepally G., Reynolds C., Tomaski A., et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995, 104:648-654.
85. Schmitt B.P., Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993, 305:208-215.
86. Visentin G.P., Malik M., Cyganiak K.A., et al. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med 1996, 128:376-383.
87. Cuker A., Ortel T.L. ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?. Hematology Am Soc Hematol Educ Program 2009, 250-252.
88. Denys B., Devreese K. A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia: an update. Thromb Res 2009, 124:642-643.
89. Morel-Kopp M.C., Aboud M., Tan C.W., et al. Heparin-induced thrombocytopenia: evaluation of IgG and IgGAM ELISA assays. Int J Lab Hematol 2011, 33:245-250.
90. Pouplard C., Leroux D., Regina S., et al. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010, 103:145-150.
91. Althaus K., Strobel U., Warkentin T.E., et al. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res 2011, 128:256-260.
92. Whitlatch N.L., Kong D.F., Metjian A.D., et al. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 2010, 116:1761-1766.
93. Warkentin T.E. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program 2011, 2011:143-149.
94. Walenga J.M., Jeske W.P., Wood J.J., et al. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin Hematol 1999, 36:22-28.
95. Tomer A., Masalunga C., Abshire T.C. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Am J Hematol 1999, 61:53-61.
96. Walenga J.M., Jeske W.P., Fasanella A.R., et al. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999, 25(Suppl 1):43-49.
97. Price E.A., Hayward C.P., Moffat K.A., et al. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost 2007, 98:1357-1361.
98. Warkentin T.E., Greinacher A., Koster A., et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:340S-380S.
99. Lewis B.E., Wallis D.E., Berkowitz S.D., et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838-1843.
100. Hursting M.J., Soffer J. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf 2009, 32:203-218.
101. Hursting M.J., Zehnder J.L., Joffrion J.L., et al. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 1999, 45:409-412.
102. Arpino P.A., Demirjian Z., Van Cott E.M. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 2005, 25:157-164.
103. Bartholomew J.R., Pietrangeli C.E., Hursting M.J. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 2007, 24:489-499.
104. Hoffman W.D., Czyz Y., McCollum D.A., et al. Reduced argatroban doses after coronary artery bypass graft surgery. Ann Pharmacother 2008, 42:309-316.
105. Hursting M.J., Verme-Gibboney C.N. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J Cardiovasc Pharmacol 2008, 52:561-566.
106. Swan S.K., Hursting M.J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000, 20:318-329.
107. Choice of drugs for heparin-induced thrombocytopenia. Med Lett Drugs Ther 2012, 54:43-44.
108. Mahaffey K.W., Lewis B.E., Wildermann N.M., et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003, 15:611-616.
109. Kiser T.H., Burch J.C., Klem P.M., et al. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2008, 28:1115-1124.
110. Dang C.H., Durkalski V.L., Nappi J.M. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006, 26:461-468.
111. Savi P., Chong B.H., Greinacher A., et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005, 105:139-144.
112. Lobo B., Finch C., Howard A., et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008, 99:208-214.
113. Grouzi E., Kyriakou E., Panagou I., et al. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost 2010, 16:663-667.
114. Goldfarb M.J., Blostein M.D. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. J Thromb Haemost 2011, 9:2501-2503.
115. Warkentin T.E., Pai M., Sheppard J.I., et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 2011, 9:2389-2396.
116. GlaxoSmithKline. Arixtra prescribing information. Available at: Accessed March 27, 2013. http://us.gsk.com/products/assets/us_arixtra.pdf.
117. Bartholomew J.R., Hursting M.J. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis 2005, 19:183-188.
118. Babcock R.B., Dumper C.W., Scharfman W.B. Heparin-induced immune thrombocytopenia. N Engl J Med 1976, 295:237-241.
119. Refaai M.A., Chuang C., Menegus M., et al. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 2010, 8:1419-1421.
120. Zucker M.B., Katz I.R. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991, 198:693-702.
121. Wanaka K., Matsuo T., Matsuo M., et al. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost 2010, 8:616-618.
122. Nuttall G.A., Oliver W.C., Santrach P.J., et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg 2003, 96:344-350. table of contents.
123. Bakchoul T., Giptner A., Bein G., et al. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 2011, 127:345-348.
124. Legnani C., Cini M., Pili C., et al. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost 2010, 104:402-409.
125. Eichler P., Raschke R., Lubenow N., et al. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002, 116:887-891.
126. GlaxoSmithKline. Argatroban prescribing information. Available at: Accessed March 26, 2013. http://www.gsksource.com/gskprm/htdocs/documents/ARGATROBAN.PDF.
127. Company TM. Angiomax prescribing information. Available at: Accessed March 26, 2013. http://www.angiomax.com/downloads/Angiomax%20US%20PI-%20PN%201601-15.pdf.